Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma

NCT00942162 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00942162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00942162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2009
Completion date
April 1, 2015
Enrollment
125 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma